{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T07:23:18Z","timestamp":1794640998472,"version":"4.9.1"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Lancet Regional Health - Europe"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.lanepe.2026.101840","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T15:22:24Z","timestamp":1788448944000},"page":"101840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement"],"prefix":"10.1016","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7020-0695","authenticated-orcid":false,"given":"Jorge C\u00e9sar","family":"Correia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9649-6615","authenticated-orcid":false,"given":"Jennifer Lyn","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Boyland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Busetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubom\u00edra","family":"F\u00e1bryov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1474-8175","authenticated-orcid":false,"given":"Tryggvi","family":"Helgason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Sbraccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euan","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Yumuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8720-3833","authenticated-orcid":false,"given":"Zoltan","family":"Pataky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10431","key":"10.1016\/j.lanepe.2026.101840_bib1","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1016\/S0140-6736(23)02750-2","article-title":"Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults","volume":"403","author":"Phelps","year":"2024","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101840_bib2","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1038\/s41591-026-04397-4","article-title":"Framework for the pharmacological treatment of obesity and its complications from the European Association for the Study of Obesity (EASO): 2026 update","volume":"32","author":"Ciudin","year":"2026","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101840_bib3","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000370038","article-title":"Need for a paradigm shift in adult overweight and obesity management - an EASO position statement on a pressing public health, clinical and scientific challenge in Europe","volume":"7","author":"Fr\u00fchbeck","year":"2014","journal-title":"Obes Facts"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101840_bib4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1159\/000362191","article-title":"An EASO position statement on multidisciplinary obesity management in adults","volume":"7","author":"Yumuk","year":"2014","journal-title":"Obes Facts"},{"issue":"6","key":"10.1016\/j.lanepe.2026.101840_bib5","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1159\/000442721","article-title":"European guidelines for obesity management in adults","volume":"8","author":"Yumuk","year":"2015","journal-title":"Obes Facts"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101840_bib6","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","article-title":"GLP-1-based therapies for diabetes, obesity and beyond","volume":"24","author":"Drucker","year":"2025","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101840_bib7","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/s41591-025-04124-5","article-title":"The expanding landscape of GLP-1 medicines","volume":"32","author":"Drucker","year":"2026","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101840_bib8","article-title":"Tirzepatide for adults living with obesity","volume":"10","author":"Franco","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101840_bib9","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1038\/s41591-024-02996-7","article-title":"Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial","volume":"30","author":"Ryan","year":"2024","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.lanepe.2026.101840_bib10","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101840_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101840_bib12","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction\u2013associated steatohepatitis: november 2025 updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.lanepe.2026.101840_bib13","article-title":"World Health Organization Guideline on the use and indications of glucagon-like Peptide-1 therapies for the treatment of obesity in adults","author":"Celletti","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.lanepe.2026.101840_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085304","article-title":"Weight regain after cessation of medication for weight management: systematic review and meta-analysis","volume":"392","author":"West","year":"2026","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.lanepe.2026.101840_bib15","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1111\/dom.14725","article-title":"Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension","volume":"24","author":"Wilding","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"14","key":"10.1016\/j.lanepe.2026.101840_bib16","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101840_bib17","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1001\/jama.2023.24945","article-title":"Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial","volume":"331","author":"Aronne","year":"2024","journal-title":"JAMA"},{"issue":"10545","key":"10.1016\/j.lanepe.2026.101840_bib18","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/S0140-6736(26)00656-2","article-title":"Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial","volume":"407","author":"Horn","year":"2026","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101840_bib19","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s11695-024-07654-y","article-title":"The landscape of obesity education worldwide \u2014 are we doing enough? Scoping review of content of obesity educational interventions in medical schools and residency programs","volume":"35","author":"Elhag","year":"2025","journal-title":"Obes Surg"},{"issue":"2","key":"10.1016\/j.lanepe.2026.101840_bib20","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41366-019-0453-6","article-title":"Obesity education in medical schools, residencies, and fellowships throughout the world: a systematic review","volume":"44","author":"Mastrocola","year":"2020","journal-title":"Int J Obes"},{"key":"10.1016\/j.lanepe.2026.101840_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12909-020-1925-z","article-title":"Low priority of obesity education leads to lack of medical students\u2019 preparedness to effectively treat patients with obesity: results from the U.S. medical school obesity education curriculum benchmark study","volume":"20","author":"Butsch","year":"2020","journal-title":"BMC Med Educ"},{"issue":"Suppl 2","key":"10.1016\/j.lanepe.2026.101840_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/dom.16364","article-title":"Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies","volume":"27","author":"Thomsen","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101840_bib23","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40265-025-02263-0","article-title":"Safety and tolerability of glucagon-like Peptide-1 receptor agonists: a state-of-the-art narrative review","volume":"86","author":"Kunutsor","year":"2026","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.lanepe.2026.101840_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004871","article-title":"Glucagon-like peptide-1 receptor agonists for obesity: growing popularity met with growing questions over safety","volume":"23","author":"Chao","year":"2026","journal-title":"PLoS Med"},{"issue":"10","key":"10.1016\/j.lanepe.2026.101840_bib25","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1007\/s00125-023-05962-z","article-title":"Socioeconomic aspects of incretin-based therapy","volume":"66","author":"Karagiannis","year":"2023","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.lanepe.2026.101840_bib26","first-page":"342","article-title":"Understanding insurance coverage policies for incretin mimetics for weight management","volume":"31","author":"Griauzde","year":"2025","journal-title":"Am J Manag Care"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101840_bib27","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2025-0083","article-title":"Affordable access to GLP-1 obesity medications: strategies to guide market action and policy solutions in the US","volume":"14","author":"Pearson","year":"2025","journal-title":"J Comp Eff Res"},{"issue":"12","key":"10.1016\/j.lanepe.2026.101840_bib28","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamasurg.2025.4385","article-title":"Costs of cutting Weight-An economic evaluation of GLP-1 agonists vs gastric bypass","volume":"160","author":"Luo","year":"2025","journal-title":"JAMA Surg"},{"issue":"4","key":"10.1016\/j.lanepe.2026.101840_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2025.0905","article-title":"Fiscal impact of expanded medicare coverage for GLP-1 receptor agonists to treat obesity","volume":"6","author":"Hwang","year":"2025","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.lanepe.2026.101840_bib30","series-title":"Therapeutic patient education: an introductory guide","year":"2023"},{"issue":"5","key":"10.1016\/j.lanepe.2026.101840_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/osp4.70012","article-title":"Factors that influence general practitioners\u2019 obesity-related clinical practices and determinants of behavior to target to promote best practice in obesity care: a qualitative exploration","volume":"10","author":"Ryan","year":"2024","journal-title":"Obes Sci Pract"},{"issue":"9","key":"10.1016\/j.lanepe.2026.101840_bib32","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41591-024-03095-3","article-title":"A new framework for the diagnosis, staging and management of obesity in adults","volume":"30","author":"Busetto","year":"2024","journal-title":"Nat Med"},{"key":"10.1016\/j.lanepe.2026.101840_bib33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/dom.15728","article-title":"Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies","volume":"26 Suppl 4","author":"Neeland","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.lanepe.2026.101840_bib34","series-title":"European Health Data Space (EHDS)","year":"2025"}],"container-title":["The Lancet Regional Health - Europe"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666776226002528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T15:17:11Z","timestamp":1793632631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666776226002528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":34,"alternative-id":["S2666776226002528"],"URL":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101840","relation":{},"ISSN":["2666-7762"],"issn-type":[{"value":"2666-7762","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrating incretin-based therapies into comprehensive obesity care: an EASO position statement","name":"articletitle","label":"Article Title"},{"value":"The Lancet Regional Health - Europe","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lanepe.2026.101840","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101840"}}